DK1991564T3 - Virosomlignende vesikler omfattende gp41-afledte antigener - Google Patents

Virosomlignende vesikler omfattende gp41-afledte antigener

Info

Publication number
DK1991564T3
DK1991564T3 DK07733909.1T DK07733909T DK1991564T3 DK 1991564 T3 DK1991564 T3 DK 1991564T3 DK 07733909 T DK07733909 T DK 07733909T DK 1991564 T3 DK1991564 T3 DK 1991564T3
Authority
DK
Denmark
Prior art keywords
virosome
vesicles
derived antigens
antigens
derived
Prior art date
Application number
DK07733909.1T
Other languages
English (en)
Inventor
Morgane Bomsel
Sylvain Fleury
Rinaldo Zurbriggen
Original Assignee
Mymetics Corp
Inst Nat Sante Rech Med
Pevion Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mymetics Corp, Inst Nat Sante Rech Med, Pevion Biotech Ltd filed Critical Mymetics Corp
Application granted granted Critical
Publication of DK1991564T3 publication Critical patent/DK1991564T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018Lipids, e.g. in lipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07733909.1T 2006-03-03 2007-03-02 Virosomlignende vesikler omfattende gp41-afledte antigener DK1991564T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2006/000466 WO2007099387A1 (en) 2006-03-03 2006-03-03 Virosome-like vesicles comprising gp41-derived antigens
PCT/IB2007/000502 WO2007099446A2 (en) 2006-03-03 2007-03-02 Virosome-like vesicles comprising gp41-derived antigens

Publications (1)

Publication Number Publication Date
DK1991564T3 true DK1991564T3 (da) 2013-12-16

Family

ID=37027640

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07733909.1T DK1991564T3 (da) 2006-03-03 2007-03-02 Virosomlignende vesikler omfattende gp41-afledte antigener

Country Status (13)

Country Link
US (1) US9216156B2 (da)
EP (1) EP1991564B1 (da)
CN (1) CN101437841B (da)
AP (1) AP2008004615A0 (da)
BR (1) BRPI0708519B8 (da)
CA (1) CA2644282C (da)
DK (1) DK1991564T3 (da)
EA (1) EA018084B1 (da)
ES (1) ES2437585T3 (da)
PL (1) PL1991564T3 (da)
PT (1) PT1991564E (da)
WO (2) WO2007099387A1 (da)
ZA (1) ZA200807592B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004291277A1 (en) * 2003-11-05 2005-06-02 Intercell Ag Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
ATE536175T1 (de) 2004-09-17 2011-12-15 Univ Massachusetts Zusammensetzungen und ihre verwendungen bei lysosomalen enzymstörungen
WO2009058913A2 (en) * 2007-10-29 2009-05-07 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
NZ588663A (en) * 2008-04-21 2013-12-20 Marine Biotechnology Australia Pty Ltd Anti-viral nutraceutical
CN102365095B (zh) * 2009-02-06 2015-11-25 麦米提斯公司 分裂gp41
US8765137B2 (en) 2009-02-06 2014-07-01 Mymetics Corporation Gp41 antigens
WO2011128720A1 (en) 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108129554A (zh) 2010-08-10 2018-06-08 洛桑聚合联合学院 红细胞结合性治疗剂
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603241A2 (en) * 2010-08-11 2013-06-19 Jv Bio Srl Multimeric inhibitors of viral fusion and uses thereof
EP2646107A2 (en) 2010-12-01 2013-10-09 Spinal Modulation Inc. Agent delivery systems for selective neuromodulation
WO2015000831A1 (en) * 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2015140648A2 (en) 2014-02-21 2015-09-24 Ecole Polytecnique Federale De Lausanne (Epfl) Epfl-Tto Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2016039619A1 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
WO2017044940A1 (en) * 2015-09-10 2017-03-16 Washington State University Cell membrane-formed nanoscale vesicles and methods of using thereof
MX2019013312A (es) 2017-05-08 2020-08-17 Flagship Pioneering Innovations V Inc Composiciones para facilitar la fusion de membranas y usos de estas.
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
CN107462534B (zh) * 2017-08-15 2019-11-29 吉林师范大学 一种检测生物巯基化合物的体系及其检测方法
EP3752623A1 (en) 2018-02-17 2020-12-23 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
US20210228627A1 (en) 2018-05-15 2021-07-29 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
KR20210043574A (ko) 2018-07-09 2021-04-21 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소좀 조성물 및 이의 용도
JP2022507453A (ja) 2018-11-14 2022-01-18 フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド T細胞送達のためのフソソーム組成物
WO2020102578A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
CA3120282A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
EP3880179A2 (en) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
WO2020121062A1 (en) 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
CN111560352B (zh) * 2020-06-02 2023-03-24 新疆农业大学 一种病毒样囊泡及其制备方法和应用
WO2022047316A1 (en) 2020-08-28 2022-03-03 Sana Biotechnology, Inc. Modified anti-viral binding agents
WO2023077107A1 (en) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
WO2023102550A2 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655823B2 (en) 1991-05-08 1995-01-12 Crucell Switzerland Ag Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
AU2003249030A1 (en) 2002-07-15 2004-02-02 Aviza Technology, Inc. Servomotor control system and method in a semiconductor manufacturing environment
CN100488491C (zh) 2002-11-21 2009-05-20 派维翁生物技术有限公司 高效融合小泡,其制备方法和含有该小泡的药物组合物
US7198791B2 (en) 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
US7919100B2 (en) 2003-07-30 2011-04-05 Mymetics Corporation Soluble and stabilized trimeric form of gp41 polypeptides
AU2004291277A1 (en) 2003-11-05 2005-06-02 Intercell Ag Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
US8147840B2 (en) * 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid

Also Published As

Publication number Publication date
WO2007099446A3 (en) 2008-06-19
ES2437585T3 (es) 2014-01-13
BRPI0708519A8 (pt) 2019-01-08
US20090202622A1 (en) 2009-08-13
BRPI0708519B1 (pt) 2019-04-16
US9216156B2 (en) 2015-12-22
ZA200807592B (en) 2009-12-30
CA2644282C (en) 2017-06-13
WO2007099387A1 (en) 2007-09-07
CN101437841B (zh) 2013-07-24
PT1991564E (pt) 2013-11-25
EP1991564B1 (en) 2013-09-11
EP1991564A2 (en) 2008-11-19
EA018084B1 (ru) 2013-05-30
CA2644282A1 (en) 2007-09-07
EA200801798A1 (ru) 2009-06-30
CN101437841A (zh) 2009-05-20
PL1991564T3 (pl) 2014-04-30
AP2008004615A0 (en) 2008-10-31
WO2007099446A2 (en) 2007-09-07
BRPI0708519B8 (pt) 2021-05-25
BRPI0708519A2 (pt) 2011-05-31

Similar Documents

Publication Publication Date Title
DK1991564T3 (da) Virosomlignende vesikler omfattende gp41-afledte antigener
ATE450271T1 (de) Impfstoff
DK2068886T3 (da) Lipidholdige præparater
DK2234600T3 (da) Antistofformulering
ES1065655Y (es) Helicoptero
CR10571A (es) Vacuna virica recombinante
DK2051606T3 (da) Lænestol
DE502006006067D1 (de) Ng
DE602007008903D1 (de) Auspuffrohrstruktur
DE602007001051D1 (de) Projektor
FI20060917A0 (fi) Tahtikone
DE602007000612D1 (de) Projektor
DE502007000429D1 (de) Kinderhochstuhl
DE502007001011D1 (de) Kinderhochstuhl
ES1062366Y (es) Interruptor-seccionador aereo
ITMN20060046A1 (it) Aereo
TH110653B (th) P-แคดฮีรินแอนติบอดี
TH122323B (th) สูตรผสมวัคซีนชนิดใหม่
UA14268S (uk) Респіратор
UA13753S (uk) Респіратор
UA12964S (uk) Респіратор
ATE448844T1 (de) Helikopter
UA13744S (uk) Каністра
ITTO20060734A1 (it) Elicottero
FI20060582A0 (fi) Farmaseuttinen valmiste